We conducted a meta-analysis of 18 RCTs involving 10909 patients to investigate the efficacy of PD-1/PD-L1 inhibitors in patients with advanced malignant tumors in different clinicopathological characteristic subgroups. This evidence concerns the gene PDCD1 and cancer.